APOBEC3A and breast carcinoma: We found that the clones of breast cancer cell line BT-474 showed significantly fewer SGMs upon APOBEC3A KO compared to control clones with wild-type (WT) APOBEC3A, while APOBEC3B knockdown led to no significant differences in SGM burden (Fig. 4F).